# Philippines Chemicals Export Opportunities (HS 28-38) ![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp) > Yugalinks sector export playbook Explore Philippines HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities. ## Overview - Exporter: Philippines (PHL) - Sector: Chemicals - HS chapters: HS 28-38 - Latest trade year: 2024 - Sector exports: $234.4M - Products: 33 - Buyer markets: 24 - Average CAGR: +18.9% - Global sector size: $580.7B ## Product portfolio | Product | Global size | Your exports | Opportunity | CAGR | Markets | Share | | --- | ---: | ---: | ---: | ---: | ---: | ---: | | HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $299.6B | $5.8M | $113.5B | -6.8% | 20 | +0.0% | | HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $94.8B | $4.1K | $35.1B | +10.1% | 4 | +0.0% | | HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $21.8B | $43.7M | $16.1B | +25.5% | 7 | +0.1% | | HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $25.6B | $118.1K | $13.4B | +296.5% | 5 | +0.0% | | HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $13.4B | $6.2M | $12.3B | +6.0% | 5 | +0.1% | | HS 300220 - Vaccines: for human medicine | $11.9B | $73.8K | $12.0B | -11.1% | 4 | +0.0% | | HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $42.3K | $10.7B | +1.0% | 3 | +0.0% | | HS 284190 - Salts of oxometallic or peroxometallic acids: n.e.c. in heading no. 2841 | $5.0B | $39.4K | $7.4B | +5.0% | 3 | +0.0% | | HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $15.1B | $33.6K | $6.3B | +13.4% | 3 | +0.0% | | HS 290110 - Acyclic hydrocarbons: saturated | $3.5B | $253.1K | $6.2B | +13.2% | 3 | +0.1% | | HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $14.9B | $535.9K | $5.9B | +5.7% | 2 | +0.0% | | HS 290919 - Ethers: acyclic, and their halogenated, sulphonated, nitrated or nitrosated derivatives, other than diethyl ether | $5.0B | $567.8K | $5.6B | +3.1% | 3 | +0.0% | | HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $10.9B | $56.2 | $4.7B | -13.7% | 2 | +0.0% | | HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $5.8B | $479.2 | $4.6B | -18.5% | 1 | +0.0% | | HS 330300 - Perfumes and toilet waters | $6.6B | $593.2K | $4.1B | +4.9% | 2 | +0.0% | | HS 290220 - Cyclic hydrocarbons: benzene | $4.1B | $89.6M | $3.3B | +35.4% | 1 | +2.2% | | HS 381800 - Chemical elements: doped for use in electronics, in the form of discs, wafers or similar forms: chemical compounds doped for use in electronics | $5.7B | $285.4K | $3.3B | +4.0% | 2 | +0.0% | | HS 284410 - Uranium: natural uranium and its compounds, alloys, dispersions (including cermets), ceramic products and mixtures containing natural uranium or natural uranium compounds | $2.8B | $32.2 | $2.6B | -46.1% | 2 | +0.0% | | HS 290121 - Acyclic hydrocarbons: unsaturated, ethylene | $1.8B | $9.7M | $2.4B | +6.2% | 1 | +0.5% | | HS 285390 - Phosphides, chemically defined or not, not ferrophosphorus: other inorganic compounds n.e.c. (including distilled, conductivity water and water of like purity): liquid air, rare gases removed or not: compressed air: amalgams, not precious metal amalgams | $1.3B | $2.9K | $2.4B | +2.4% | 1 | +0.0% | | HS 290531 - Alcohols: acyclic, diols: ethylene glycol (ethanediol) | $3.2B | $28.4K | $2.2B | +8.1% | 1 | +0.0% | | HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $57.9 | $2.0B | -3.9% | 1 | +0.0% | | HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $1.3B | $33.7M | $1.9B | +26.7% | 1 | +2.5% | | HS 290122 - Acyclic hydrocarbons: unsaturated, propene (propylene) | $1.6B | $34.3M | $1.8B | +28.4% | 1 | +2.1% | | HS 370790 - Photographic goods: chemical preparations other than sensitised emulsions, put up in measured portions or put up for retail sale in a form ready for use | $2.2B | $12.9K | $1.8B | +5.3% | 1 | +0.0% | | HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $1.4B | $418.7K | $1.7B | +35.3% | 1 | +0.0% | | HS 300670 - Pharmaceutical goods: Gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments | $1.2B | $1.1 | $1.4B | -37.8% | 1 | +0.0% | | HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $6.6K | $1.4B | +38.7% | 1 | +0.0% | | HS 284690 - Compounds, inorganic or organic (excluding cerium), of rare-earth metals, of yttrium, scandium or of mixtures of these metals | $1.4B | $3.4M | $1.4B | +28.2% | 1 | +6.8% | | HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $875.7M | $9.1 | $1.3B | -24.5% | 1 | +0.0% | | HS 382370 - Industrial fatty alcohols | $1.0B | $5.0M | $1.3B | +7.0% | 1 | +0.5% | | HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $1.8B | $5.9K | $1.2B | -0.5% | 1 | +0.0% | | HS 300214 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail sale | $2.2B | $40.2 | $1.2B | -60.8% | 1 | +0.0% | ## Best markets - USA, Puerto Rico and US Virgin Islands (USA): $77.3B calculated opportunity across 14 products. - China (CHN): $39.7B calculated opportunity across 16 products. - Switzerland, Liechtenstein (CHE): $35.1B calculated opportunity across 4 products. - Germany (DEU): $22.1B calculated opportunity across 6 products. - Belgium (BEL): $19.6B calculated opportunity across 4 products. - Mexico (MEX): $10.7B calculated opportunity across 5 products. - Netherlands (NLD): $10.6B calculated opportunity across 4 products. - Slovenia (SVN): $9.7B calculated opportunity across 1 products. - Canada (CAN): $9.4B calculated opportunity across 5 products. - United Kingdom (GBR): $8.8B calculated opportunity across 4 products. - Spain (ESP): $7.7B calculated opportunity across 3 products. - Republic of Korea (KOR): $7.0B calculated opportunity across 4 products. ## Growth stars - HS 300212: +296.5% average CAGR, $13.4B calculated opportunity. - HS 340220: +38.7% average CAGR, $1.4B calculated opportunity. - HS 290220: +35.4% average CAGR, $3.3B calculated opportunity. - HS 381512: +35.3% average CAGR, $1.7B calculated opportunity. - HS 290122: +28.4% average CAGR, $1.8B calculated opportunity. - HS 284690: +28.2% average CAGR, $1.4B calculated opportunity. - HS 382319: +26.7% average CAGR, $1.9B calculated opportunity. - HS 382499: +25.5% average CAGR, $16.1B calculated opportunity. - HS 382200: +13.4% average CAGR, $6.3B calculated opportunity. - HS 290110: +13.2% average CAGR, $6.2B calculated opportunity. ## Diversification opportunities - HS 300490: 20 buyer markets, $113.5B calculated opportunity. - HS 382499: 7 buyer markets, $16.1B calculated opportunity. - HS 300212: 5 buyer markets, $13.4B calculated opportunity. - HS 382600: 5 buyer markets, $12.3B calculated opportunity. - HS 300215: 4 buyer markets, $35.1B calculated opportunity. - HS 300220: 4 buyer markets, $12.0B calculated opportunity. - HS 330210: 3 buyer markets, $10.7B calculated opportunity. - HS 284190: 3 buyer markets, $7.4B calculated opportunity. - HS 382200: 3 buyer markets, $6.3B calculated opportunity. - HS 290110: 3 buyer markets, $6.2B calculated opportunity. ## Method Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology). ## Data sources - Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/) - CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf) This page presents derived Yugalinks views of reported observations and calculated indicators.